Method for realizing quantitative analysis on Lovastatin acid and HMG-CoA reductase inhibitor in human plasma

A reductase inhibitor, hydroxylovastatin acid technology, applied in the field of quantitative analysis of lovastatin acid and other HMG-CoA reductase inhibitors, can solve the problem of quantitative analysis of HMG-CoA reductase inhibitors Reporting and other issues

Active Publication Date: 2012-03-21
BEIJING WBL PEKING UNIV BIOTECH
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The technical methods reported in the literature are all quantitative analysis methods for a single statin. Since statin acids, the plasma metabolites of statins, also have certain HMG-CoA reductase inhibitory activity, the quantitative analysis of the content of statins in plasma cannot be true. Response of this statin to HMG-CoA reductase inhibitory activity
There is no methodological report on the quantitative analysis of HMG-CoA reductase inhibitors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for realizing quantitative analysis on Lovastatin acid and HMG-CoA reductase inhibitor in human plasma
  • Method for realizing quantitative analysis on Lovastatin acid and HMG-CoA reductase inhibitor in human plasma
  • Method for realizing quantitative analysis on Lovastatin acid and HMG-CoA reductase inhibitor in human plasma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0231] Embodiment 1: quantitative analysis method of the present invention

[0232] A. Preparation of reagent solution

[0233] (1) Preparation of 200mM Potassium Dihydrogen Phosphate Buffer (pH7.4, PBS)

[0234] Weigh 10.6g K 3 PO 4 ·3H 2 O in a beaker, add 180mL water to dissolve, and use H 3 PO 4 Adjust the pH to 7.4, then add pure water to 200mL, shake well;

[0235] (2) Preparation of 200mM EDTA (ethylenediaminetetraacetic acid) (in PBS of 200mM pH7.4)

[0236] Add 162mg K to 200mL pH7.4, 200mM PBS 2 EDTA·2H 2 O (dipotassium edetate), shake well;

[0237] (3) Preparation of 10mM DTT (dithiothreitol) (in 2mM EDTA and 200mM PBS (PH7.4)) Take 15.4mg DTT into a 10mL volumetric flask, and dilute to the mark with 2mM EDTA;

[0238] (4) Preparation of 12mM NADPH (reduced coenzyme II)

[0239] Take 20mg NADPH·Na 4 Add 2mL of pure water to a 5mL plastic tube, dissolve and mix well, store at -20°C for later use;

[0240] (5) Preparation of 0.4mM HMG-CoA

[0241] Add 1...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
recovery rateaaaaaaaaaa
Login to view more

Abstract

The invention discloses a method for realizing the quantitative analysis on Lovastatin acid and other HMG-CoA reductase inhibitors in human plasma by measuring HMG-CoA reductase inhibitor. By the confirmation of a test on the applicability of the method, when being used for testing the inhibitory activity of Lovastatin acid and other HMG-CoA reductase inhibitors in human plasma, the method can meet the requirements of methodology, so that the method can be applicable to bioresearches. All data can satisfy the acceptance standards of experiment design.

Description

field of invention [0001] The present invention relates to a method for quantitative analysis of lovastatin acid and other HMG-CoA reductase inhibitors in human plasma, in particular to a method for quantitatively analyzing lovastatin acid and other HMG in human plasma by measuring the activity of HMG-CoA reductase - A method of a CoA reductase inhibitor. Background technique [0002] HMG-CoA reductase is the key enzyme of cholesterol synthesis, inhibiting HMG-CoA reductase can limit the synthesis of cholesterol and achieve the purpose of regulating blood lipids. Currently, HMG-CoA reductase inhibitors mainly include lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin and the like. The technical methods reported in the literature are all quantitative analysis methods for a single statin. Since statin acids, the plasma metabolites of statins, also have certain HMG-CoA reductase inhibitory activity, quantitative analysis of the content of statins in ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N30/88
Inventor 段震文郭树仁
Owner BEIJING WBL PEKING UNIV BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap